Methods of treatment using anti-erbb antibody-maytansinoid conjugates
AssigneesImmunoGen, Inc., Genentech, Inc.
InventorsWalter Blattler, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
Life of this patent
Estimating the term…
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
Claims36
A method for treatment of cancer that expresses ErbB2 in a mammal, the method comprising administering an anti-ErbB2 antibody-maytansinoid conjugate, wherein the anti-ErbB2 antibody is a growth inhibitory antibody that binds to ErbB2 and inhibits the growth of cancer cells overexpressing ErbB2.
An anti-ErbB2 antibody-maytansinoid conjugate, wherein the anti-ErbB2 antibody is a growth inhibitory antibody that binds to ErbB2 and inhibits the growth of cancer cells overexpressing ErbB2.
Dependencies are inferred from the claim text.